DNA-Based Colon Cancer Test Gets FDA Nod

the MPR take:

An FDA advisory panel has unanimously recommended approval of the Cologuard screening test, manufactured by Exact Sciences. Although colonoscopy is the standard for for colon cancer and polyps detection, a large clinical trial of the DNA test detected 92.3% of colorectal cancers in average-risk patients. The test evaluates a combination of DNA and hemoglobin markers present in abnormal cells shed in the stool; if the test results are positive for cancer, the patient would need to undergo a colonoscopy. 

DNA-Based Colon Cancer Test Gets FDA Nod
DNA-Based Colon Cancer Test Gets FDA Nod
A panel of outside experts to the Food and Drug Administration voted 10-0 to recommend approval of the Cologuard screening test made by Exact Sciences Corp. If Cologuard is approved by the FDA, patients who have a positive cancer finding with the test, which identifies abnormal cells shed in the ...

READ FULL ARTICLE From Reuters

Loading links....